Faculty of Medicine and Health Sciences, University Of Auckland, Auckland, New Zealand.
Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Kaohsiung J Med Sci. 2021 May;37(5):355-360. doi: 10.1002/kjm2.12368. Epub 2021 Mar 2.
Vascular liver disease (VLD) presents special challenges in the diagnosis, surveillance, and treatment of hepatocellular carcinoma (HCC). HCC arising in the setting of vascular liver disease is often thought to be due to elevated hepatic arterial blood flow, rather than progressive fibrosis from chronic inflammation as with other chronic liver conditions such as viral hepatitis, autoimmune, and metabolic liver diseases. Vascular alteration inherent in VLD often impedes HCC non-invasive diagnosis and loco-regional treatment that depend on vascular properties found in typical liver environment. Benign and pre-malignant liver nodules such as focal nodular hyperplasia and hepatocellular adenoma are also more common in certain VLDs, further adding to surveillance and diagnostic challenges. In this synopsis, we aimed to review available literature on the epidemiology, surveillance, diagnosis, and management of HCC in patients with VLD and specifically Budd-Chiari syndrome, congenital porto-systemic shunts, Fontan-associated liver disease, hereditary hemorrhagic telangiectasia.
血管性肝病(VLD)在肝细胞癌(HCC)的诊断、监测和治疗方面带来了特殊挑战。血管性肝病中发生的 HCC 通常被认为是由于肝动脉血流升高引起的,而不是像病毒性肝炎、自身免疫性和代谢性肝病等其他慢性肝病那样由慢性炎症引起的进行性纤维化。VLD 中固有的血管改变常常阻碍了 HCC 的非侵入性诊断和局部区域治疗,这些治疗依赖于在典型肝脏环境中发现的血管特性。良性和癌前肝脏结节,如局灶性结节性增生和肝细胞腺瘤,在某些 VLD 中也更为常见,这进一步增加了监测和诊断的挑战。在这篇综述中,我们旨在回顾 VLD 患者(特别是布加综合征、先天性门体分流、Fontan 相关肝病、遗传性出血性毛细血管扩张症)中 HCC 的流行病学、监测、诊断和管理方面的现有文献。